Study drug combination for esophageal cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs (a type of immunotherapy called adebrelimab and an immune-boosting drug called thymalfasin) given with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve the chances of a successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been diagnosed with squamous cell carcinoma of the esophagus.
- You must not have had any prior treatment for esophageal cancer.
- You must be healthy enough to undergo surgery and general anesthesia.
- You must have adequate organ and bone marrow function, as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab (an immunotherapy) given before surgery to treat esophageal squamous cell cancer. It compares 2 cycles of treatment with 4 cycles to see which works better. The goal is to shrink the tumor and make surgery more effective.
This study tests a new combination of drugs (adebelimab, apatinib, and chemotherapy or chemoradiation) for people with esophageal cancer that has gotten worse after prior immunotherapy. It aims to see if this combination can help when standard first-line treatment stops working.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.